Flowchem Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 28-09-2024
- Paid Up Capital ₹ 3.10 Cr
as on 28-09-2024
- Company Age 6 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 12.50 Cr
as on 28-09-2024
- Revenue 61.06%
(FY 2023)
- Profit 45.57%
(FY 2023)
- Ebitda 95.73%
(FY 2023)
- Net Worth -91.63%
(FY 2023)
- Total Assets 25.40%
(FY 2023)
About Flowchem Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 3.10 Cr.
The company has closed loans amounting to ₹12.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Anjan Roy, Trishna Roy, Dipak Chaudhary, and One other member serve as directors at the Company.
- CIN/LLPIN
U24304KA2018PTC118418
- Company No.
118418
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Nov 2018
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Flowchem Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anjan Roy  | Director | 06-Sep-2021 | Current |
| Trishna Roy | Director | 15-Jun-2023 | Current |
| Dipak Chaudhary | Director | 12-Nov-2018 | Current |
| Arun Biradar | Director | 28-Dec-2023 | Current |
Financial Performance of Flowchem Pharma.
Flowchem Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 61.06% increase. The company also saw a substantial improvement in profitability, with a 45.57% increase in profit. The company's net worth observed a substantial decline by a decrease of 91.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Flowchem Pharma?
In 2023, Flowchem Pharma had a public holding of 96.77%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ray Life Sciences Private LimitedActive 33 years 3 monthsAnjan Roy and Trishna Roy are mutual person
Trroy Life Sciences Private LimitedActive 14 years 5 monthsAnjan Roy and Trishna Roy are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 27 Aug 2020 | ₹12.50 Cr | Satisfied |
How Many Employees Work at Flowchem Pharma?
Flowchem Pharma has a workforce of 96 employees as of Sep 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Flowchem Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Flowchem Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
